Pulsalys is an innovation incubator and accelerator established in 2013 and located in Villeurbanne, France. The company focuses on developing innovative products and services, primarily by investing in deep technology startups in the regions of Lyon and Saint Etienne. By fostering entrepreneurship and supporting emerging ventures, Pulsalys aims to drive technological advancement and contribute to the local economy.
Lyophitech is a manufacturer specializing in freeze-drying equipment for the pharmaceutical sector and other industries such as food and microbiology. The company utilizes patented technology to enhance freeze-drying processes, allowing for quicker and more efficient cycles. This innovative approach reduces operating time and costs, facilitating continuous operation. By addressing the challenges associated with freeze-drying, Lyophitech aims to improve the overall effectiveness of its clients' production processes while also focusing on the development of new freeze-drying technologies.
Mecaware
Series A in 2023
MECAWARE specializes in battery recycling technology aimed at recovering critical metals and rare earth elements, thus supporting the sustainable supply chain for the battery sector. The company focuses on resource circularity and enhancing strategic autonomy through innovative solutions that promote eco-efficient industrial practices. By providing services for recycling critical metals from end-of-life batteries and production scraps, MECAWARE helps its customers secure their supply of essential materials while minimizing environmental impact.
Lys Therapeutics
Non Equity Assistance in 2021
Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.